Cybin (HELP) had its price target raised by HC Wainwright from $55.00 to $95.00. They now have a "buy" rating on the stock.
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments [Globe and Mail, The (Toronto, Canada)]
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders [Globe and Mail, The (Toronto, Canada)]
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience [Seeking Alpha]
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee